Search

Your search keyword '"YAO, J. C."' showing total 3 results
Start Over Author "YAO, J. C." Publication Year Range This year
3 results on '"YAO, J. C."'

2. EFFICIENT EXTRAGRADIENT METHODS FOR BILEVEL PSEUDOMONOTONE VARIATIONAL INEQUALITIES WITH NON-LIPSCHITZ OPERATORS AND THEIR APPLICATIONS.

Author

QIN, X., PETRUŞEL, A., TAN, B., and YAO, J. C.

Subjects
HILBERT space, VARIATIONAL inequalities (Mathematics), ALGORITHMS
Abstract

In this paper, four extragradient-type algorithms are presented for solving bilevel variational inequalities of pseudomonotone and non-Lipschitz continuous operators in real Hilbert spaces. The proposed iterative schemes employ two Armijo-type linesearch methods making them work adaptively. Strong convergence theorems of the suggested algorithms are established under some mild conditions. Finally, some numerical experiments and applications are given to verify the advantages and efficiency of the proposed algorithms over some previously known ones. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study.

Author

de Sousa LG, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas EP, Cho WC, Wistuba I, Yao JC, Woodman SE, Halperin DM, and Ferrarotto R

Subjects
Humans, Bevacizumab therapeutic use, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Merkel Cell drug therapy, Skin Neoplasms drug therapy, Liver Neoplasms, Antibodies, Monoclonal, Humanized
Abstract

Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: R. Ferrarotto: Paid consultant/advisory board member for Elevar Therapeutics, Prelude Therapeutics, Regeneron, Sanofi, Eisai, and Remix. Royalties from UpToDate. Supported by research funding to MD Anderson Cancer Center from Ayala, Merck, Genentech, Pfizer, Nanobiotix, EMD Serono, Viracta, Seagen, and ISA Therapeutics. M. Altan: Supported by research funding to MD Anderson Cancer Center from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, Shattuck Lab, and Gilead. Member of the advisory board for GlaxoSmithKline, Shattuck Lab, Bristol Myers Squibb, AstraZeneca, and Insightec. Speaker fees from AstraZeneca, Nektar Therapeutics, and Society for Immunotherapy of Cancer. Participation in the safety review committee for the Nanobiotix–MD Anderson alliance Hengenix. C. Yun: shareholder of Genentech/Roche. All other authors: none.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results